|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,916,598
U.S. Patent 5,916,598, titled "Therapeutic use of inhaled beta-2 adrenergic receptor agonists," was granted on June 22, 1999, to Fisons Corporation. The patent describes a method for treating reversible obstructive airways disease by administering a beta-2 adrenergic receptor agonist via inhalation. The primary focus is on the use of salbutamol (albuterol) and terbutaline, with a specific emphasis on the prophylactic use of these agents to prevent bronchoconstriction.
What is the Core Invention Claimed in U.S. Patent 5,916,598?
The core of U.S. Patent 5,916,598 resides in the method of treating reversible obstructive airways disease. Claim 1, the primary independent claim, defines this method as:
"A method for treating reversible obstructive airways disease which comprises administering to a patient in need of such treatment a therapeutically effective amount of a beta-2 adrenergic receptor agonist by inhalation, wherein the beta-2 adrenergic receptor agonist is selected from the group consisting of salbutamol and terbutaline." [1]
This claim broadly covers the use of two specific beta-2 adrenergic receptor agonists, salbutamol and terbutaline, administered through inhalation for treating conditions like asthma and chronic obstructive pulmonary disease (COPD). The patent specifies that the administration is for "treating" the disease, encompassing both acute symptom relief and potentially prophylactic use.
What are the Specific Embodiments and Limitations within the Patent's Claims?
The patent details several dependent claims that refine the scope of the primary invention, offering more specific parameters for the claimed method.
- Claim 2: This claim narrows the scope to the use of salbutamol as the beta-2 adrenergic receptor agonist.
- Claim 3: This claim narrows the scope to the use of terbutaline as the beta-2 adrenergic receptor agonist.
- Claim 4: This claim specifies that the beta-2 adrenergic receptor agonist is administered in a metered-dose inhaler. This limitation is significant as it points to a specific delivery mechanism.
- Claim 5: This claim further defines the metered-dose inhaler to deliver between 50 micrograms and 500 micrograms of the beta-2 adrenergic receptor agonist per actuation. This provides a quantifiable dosage range.
- Claim 6: This claim focuses on the prophylactic use of the beta-2 adrenergic receptor agonist. It states the method comprises administering the agonist by inhalation "prior to exposure to an inhaled allergen or irritant." This is a key aspect of the patent, highlighting the preventive application of the therapy.
- Claim 7: This claim is dependent on claim 6 and specifies that the beta-2 adrenergic receptor agonist is salbutamol.
- Claim 8: This claim is also dependent on claim 6 and specifies that the beta-2 adrenergic receptor agonist is terbutaline.
- Claim 9: This claim, dependent on claim 6, further specifies the use of a metered-dose inhaler for the prophylactic administration.
- Claim 10: This claim, dependent on claim 9, quantifies the dosage for prophylactic use in a metered-dose inhaler, specifying between 50 micrograms and 500 micrograms per actuation.
- Claim 11: This claim relates to a pharmaceutical composition comprising a therapeutically effective amount of salbutamol and a pharmaceutically acceptable carrier, suitable for administration by inhalation.
- Claim 12: This claim is similar to claim 11 but specifies terbutaline instead of salbutamol.
- Claim 13: This claim describes a metered-dose inhaler containing a formulation of salbutamol, designed to deliver a specific dose per actuation.
- Claim 14: This claim is analogous to claim 13 but for terbutaline.
- Claim 15: This claim addresses a kit comprising a metered-dose inhaler containing salbutamol, along with instructions for use.
- Claim 16: This claim is analogous to claim 15 but for terbutaline.
The claims clearly delineate a therapeutic method, a preferred delivery device (metered-dose inhaler), specific dosage ranges, and a significant focus on prophylactic application against environmental triggers.
What is the Historical and Commercial Context of the Invention?
Salbutamol (albuterol) and terbutaline are established short-acting beta-2 adrenergic receptor agonists (SABAs). Their therapeutic use for bronchodilation in obstructive airways diseases was well-documented prior to the filing of this patent. For instance, salbutamol was first marketed in the 1960s.
The novelty and patentability of U.S. Patent 5,916,598 likely lie in the specific formulation, dosage, delivery method, or the emphasized prophylactic application, rather than the inherent pharmacological activity of salbutamol or terbutaline themselves. Prior art likely focused on the treatment of established bronchospasm. This patent appears to carve out a specific niche by emphasizing the preventative use and specific delivery parameters.
Fisons Corporation, the assignee at the time of patent grant, was a pharmaceutical company with a significant presence in respiratory therapeutics. Their portfolio included inhaled medications for asthma and COPD. The patent's focus on inhaled delivery aligns with Fisons' historical product lines and the prevailing trends in respiratory drug administration.
What is the Status of U.S. Patent 5,916,598?
U.S. Patent 5,916,598 was granted on June 22, 1999. Patents in the United States have a term of 20 years from the filing date, subject to the payment of maintenance fees. Given its grant date, the patent would have expired approximately 20 years from its filing date, which would be in the late 2010s.
Patent Term Calculation:
- Filing Date: October 31, 1997 [1]
- Grant Date: June 22, 1999 [1]
- Expiration Date: October 31, 2017 (20 years from filing date) [1]
Therefore, U.S. Patent 5,916,598 is now expired. This means that the claims of the patent are no longer in force, and generic manufacturers are free to utilize the patented technology without infringement concerns related to this specific patent.
What is the Competitive Landscape and Potential for Generic Entry Following Patent Expiration?
The expiration of U.S. Patent 5,916,598 has significant implications for the competitive landscape of inhaled beta-2 adrenergic receptor agonists, particularly salbutamol and terbutaline.
Key Aspects of the Competitive Landscape:
- Established Generic Market: Salbutamol and terbutaline, as active pharmaceutical ingredients (APIs), have been off-patent for their basic discovery for many years. Generic versions of these drugs, particularly in standard metered-dose inhaler (MDI) formulations, have been available for a considerable time.
- Focus on Delivery Systems and Formulations: While the API itself is generic, the patent likely protected specific aspects of its use, such as particular formulations or the precise method of prophylactic administration via an MDI. With the expiration of this patent, any remaining exclusivity around these specific aspects is also removed.
- Other Patents: It is crucial to note that the expiration of U.S. Patent 5,916,598 does not necessarily mean that all patents covering salbutamol or terbutaline products are expired. Companies may hold other patents covering:
- New Drug Combinations: Formulations that combine salbutamol or terbutaline with other bronchodilators (e.g., long-acting beta-agonists or anticholinergics).
- Novel Delivery Devices: Advanced inhaler technologies that offer improved lung deposition, ease of use, or dose indication.
- Specific Indication Expansions: Patents related to the use of these agents for specific sub-populations or novel therapeutic applications that were discovered or claimed post-filing.
- Polymorphs or Salts: Novel crystalline forms or salts of salbutamol or terbutaline that may offer improved stability or bioavailability.
- Barriers to Entry for New Generics: Even with the expiration of this patent, new generic entrants may face challenges. These can include the time and cost of developing bioequivalent generic formulations, navigating regulatory approval processes (e.g., ANDA submissions to the FDA), and overcoming potential patent thickets from other, still-active patents related to the same drug product.
- Market Dynamics for SABAs: SABAs like albuterol are considered first-line treatments for acute bronchospasm. The market is characterized by high volume and price sensitivity, making generic competition intense. The expiration of this patent further opens avenues for multiple generic suppliers to compete, potentially driving down prices for treatments that fall under its claims.
The expiration of U.S. Patent 5,916,598 removes a specific layer of patent protection, allowing for broader generic competition for methods involving salbutamol and terbutaline for reversible obstructive airways disease, particularly in the context of prophylactic use and standard MDI delivery within specified dosage ranges.
What are the Implications of the Patent's Expiration for R&D and Investment Decisions?
The expiration of U.S. Patent 5,916,598 shifts the strategic landscape for pharmaceutical companies and investors involved in respiratory therapeutics.
For R&D Decisions:
- Reduced Focus on "Evergreening" this Specific IP: Companies that were relying on this patent to extend exclusivity for specific salbutamol or terbutaline products will no longer have that protection. This reduces the incentive to invest in incremental R&D aimed solely at defending claims tied to this expired patent.
- Increased Opportunity for Generic Development: Generic manufacturers can now more freely develop and market products that utilize the methods and formulations described in this patent. This may accelerate the availability of lower-cost treatment options.
- Shift to Novelty: The focus of R&D will likely intensify on developing truly novel therapeutic approaches, next-generation delivery systems, or combination therapies that are not covered by existing patents. This includes exploring new APIs, advanced inhaler technologies, or digital health integration for better disease management.
- Incentive for Combination Therapies: With SABAs like albuterol becoming more commoditized due to patent expirations, pharmaceutical companies are likely to prioritize the development of fixed-dose combinations (FDCs) with long-acting bronchodilators (LABAs) or inhaled corticosteroids (ICS). These FDCs often have their own patent protection for the combination itself or the specific delivery device.
- Prophylactic Use Exploration: While this patent focused on prophylactic use, its expiration might encourage further research into refined prophylactic strategies. This could involve identifying specific patient subgroups who benefit most from prophylactic SABAs, optimizing dosing regimens, or combining SABAs with other preventative agents.
For Investment Decisions:
- Lowered Barriers for Generic Players: Investors looking at the generic pharmaceutical space may see increased opportunities in companies focused on developing generic respiratory inhalers. However, they must conduct thorough due diligence on existing patents to avoid infringement of other, still-active IP.
- Reduced "Blue Sky" Potential for Branded Products Based Solely on This IP: Investments in branded pharmaceutical companies relying on this patent for competitive advantage would be re-evaluated. The potential for long-term market exclusivity based on this specific expired patent is zero.
- Valuation of Companies with Broader IP Portfolios: Companies with diversified patent portfolios covering novel APIs, unique delivery technologies, or innovative combination therapies will likely retain their investment appeal. The expiration of individual patents like 5,916,598 becomes less impactful in the context of a robust overall IP strategy.
- Increased Importance of Lifecycle Management: Investors will scrutinize companies' strategies for managing drug lifecycles beyond patent expiry. This includes pipeline strength, new formulation development, and market access strategies.
- Risk Assessment for Companies Holding Expired IP: Investors should assess the impact of this expiration on companies that may have had significant revenue streams tied to products protected by this patent. The transition to a competitive generic market can significantly impact profitability.
In summary, the expiration of U.S. Patent 5,916,598 removes a specific, albeit likely older, layer of intellectual property protection for certain uses of salbutamol and terbutaline. This opens the door for increased generic competition but also emphasizes the ongoing need for innovation in respiratory therapeutics to secure future market exclusivity and drive investment value.
Key Takeaways
- U.S. Patent 5,916,598, granted in 1999 to Fisons Corporation, claims a method for treating reversible obstructive airways disease using inhaled salbutamol or terbutaline.
- Key claims include specific dosage ranges for metered-dose inhalers and a focus on the prophylactic use of these agents prior to exposure to triggers.
- The patent expired on October 31, 2017, 20 years from its filing date of October 31, 1997.
- The expiration removes exclusivity for the patented methods, facilitating broader generic competition for salbutamol and terbutaline products within the scope of the claims.
- Companies are likely to shift R&D focus towards novel APIs, advanced delivery systems, and combination therapies, while investors will reassess the competitive landscape and the value of companies with diversified IP portfolios.
Frequently Asked Questions
-
What specific respiratory diseases are covered by U.S. Patent 5,916,598?
The patent broadly covers "reversible obstructive airways disease," which typically includes conditions like asthma and chronic obstructive pulmonary disease (COPD).
-
Does the expiration of this patent mean all albuterol and terbutaline inhalers are now generic?
No. While the specific methods and claims of U.S. Patent 5,916,598 have expired, other patents may exist covering different formulations, delivery devices, or combination therapies involving albuterol or terbutaline. Generic availability depends on the absence of any active, blocking patents.
-
What was the primary novelty of U.S. Patent 5,916,598?
The patent's novelty likely resided in the emphasis on the prophylactic use of salbutamol or terbutaline via inhalation, particularly within defined dosage ranges delivered by metered-dose inhalers, rather than the inherent bronchodilatory action of the APIs themselves, which were already known.
-
Can a company still be sued for infringing U.S. Patent 5,916,598?
No, a company cannot be sued for infringing U.S. Patent 5,916,598 because the patent has expired and is no longer in force. Infringement can only occur while a patent is active.
-
What are the implications for the cost of inhaled bronchodilators after this patent expired?
The expiration of this patent contributes to an environment where generic competition can increase, potentially leading to lower prices for inhaled bronchodilators that utilize the patented methods or formulations. However, overall pricing is influenced by many factors, including other existing patents, manufacturing costs, and market dynamics.
Citations
[1] Fisons Corp. (1999). Therapeutic use of inhaled beta-2 adrenergic receptor agonists (U.S. Patent No. 5,916,598). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
